{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:15:47Z","timestamp":1789416947891,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of refractory pleural effusion presents a significant clinical challenge. This study aims to compare the outcomes of thoracoscopic talc pleurodesis (TP) and indwelling pleural catheter (IPC) insertion, focusing on survival, complications, and healthcare utilization, while accounting for baseline performance status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective cohort study in 2024 at a single tertiary care center, enrolling 101 patients with refractory pleural effusion. Patients were allocated to either the IPC group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200972, 71.3%) or the TP group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929, 28.7%). Primary outcomes included overall survival, length of hospital stay, and total treatment duration. Secondary outcomes were pleurodesis success rate, effusion recurrence, and procedure-related complications. Multivariate analysis was performed to adjust for confounders including age, ECOG performance status, and etiology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The IPC group had a significantly shorter median hospital stay (1\u00a0day vs. 7\u00a0days;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Unadjusted survival was significantly lower in the IPC group compared to the TP group at 12\u00a0months (13.3% vs. 62.1%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, after adjusting for ECOG performance status and age in a multivariate Cox regression, the treatment modality was no longer an independent predictor of mortality (HR 0.78, 95% CI 0.41\u20131.48;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.45), whereas ECOG score remained a strong predictor (HR 1.65, 95% CI 1.32\u20132.06;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). TP achieved a 100% pleurodesis success rate, compared to 25.4% for IPC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). IPC patients reported less chest pain (13.9% vs. 48.3%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and bleeding (1.4% vs. 20.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A significant trade-off exists between the two procedures. IPC is associated with shorter hospitalization and fewer acute complications, while TP offers definitive effusion control. The observed survival difference in the TP group appears to be driven by the selection of fitter patients with better performance status for the more invasive procedure, rather than a direct therapeutic benefit of talc. Treatment decisions must be individualized, weighing patient prognosis and performance status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-026-04002-x","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:44:57Z","timestamp":1770306297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Talc pleurodesis versus indwelling pleural catheter for refractory pleural effusion: a prospective study of survival and complications"],"prefix":"10.1186","volume":"31","author":[{"given":"Shima","family":"Mosalanejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesam","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Abtahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Khoshnam Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Roostaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Kazemizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"4","key":"4002_CR1","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0145-2023","volume":"19","author":"LM Piggott","year":"2023","unstructured":"Piggott LM, Hayes C, Greene J, Fitzgerald DB. Malignant pleural disease. Breathe. 2023;19(4):230145. https:\/\/doi.org\/10.1183\/20734735.0145-2023.","journal-title":"Breathe"},{"issue":"7","key":"4002_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","volume":"198","author":"DJ Feller-Kopman","year":"2018","unstructured":"Feller-Kopman DJ, Reddy CB, Gould MK, et al. Management of malignant pleural effusions: an official ATS\/STS\/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198(7):839\u201349. https:\/\/doi.org\/10.1164\/rccm.201807-1415ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 2","key":"4002_CR3","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","volume":"65","author":"ME Roberts","year":"2010","unstructured":"Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32\u201340. https:\/\/doi.org\/10.1136\/thx.2010.136994.","journal-title":"Thorax"},{"issue":"1","key":"4002_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11606-010-1472-0","volume":"26","author":"MEM Van Meter","year":"2011","unstructured":"Van Meter MEM, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70\u20136. https:\/\/doi.org\/10.1007\/s11606-010-1472-0.","journal-title":"J Gen Intern Med"},{"issue":"22","key":"4002_CR5","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2012.5535","volume":"307","author":"HE Davies","year":"2012","unstructured":"Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383\u20139. https:\/\/doi.org\/10.1001\/jama.2012.5535.","journal-title":"JAMA"},{"issue":"2","key":"4002_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01215-2022","volume":"63","author":"P Sivakumar","year":"2024","unstructured":"Sivakumar P, Fitzgerald DB, Ip H, et al. The impact of outpatient versus inpatient management on health-related quality of life outcomes for patients with malignant pleural effusion: the OPTIMUM randomised clinical trial. Eur Respir J. 2024;63(2):2201215. https:\/\/doi.org\/10.1183\/13993003.01215-2022.","journal-title":"Eur Respir J"},{"key":"4002_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010529.pub3","author":"A Dipper","year":"2020","unstructured":"Dipper A, Jones HE, Bhatnagar R, Preston NJ, Maskell N, Clive AO. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD010529.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4002_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1513\/AnnalsATS.201807-495OC","volume":"16","author":"I Np","year":"2019","unstructured":"Np I, Cb R, Mm W, et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions a systematic review and meta-analysis. Ann Am Thorac Soc. 2019;16(1):124\u201331.","journal-title":"Ann Am Thorac Soc"},{"key":"4002_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1136\/thorax-2022-219784","volume":"78","author":"ME Roberts","year":"2023","unstructured":"Roberts ME, Rahman NM, Maskell NA, et al. British Thoracic Society guideline for pleural disease. Thorax. 2023;78:S1\u201342. https:\/\/doi.org\/10.1136\/thorax-2022-219784.","journal-title":"Thorax"},{"key":"4002_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00349-2018","author":"AC Bibby","year":"2018","unstructured":"Bibby AC, Dorn P, Psallidas I, et al. ERS\/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.00349-2018.","journal-title":"Eur Respir J"},{"issue":"6","key":"4002_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/op.24.00387","volume":"21","author":"M Munavvar","year":"2025","unstructured":"Munavvar M, Bodtger U, Carus A, et al. Current trends in treating malignant pleural effusion: evidence, guidelines, and best practice recommendations. JCO Oncol Pract. 2025;21(6):759\u201365. https:\/\/doi.org\/10.1200\/op.24.00387.","journal-title":"JCO Oncol Pract"},{"key":"4002_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-03023-6","author":"C Kwok","year":"2024","unstructured":"Kwok C, Thavorn K, Amjadi K, Aaron SD, Kendzerska T. Mortality after treatment of malignant pleural effusions with indwelling pleural catheters versus chemical pleurodesis: a population-based study. Respir Res. 2024. https:\/\/doi.org\/10.1186\/s12931-024-03023-6.","journal-title":"Respir Res"},{"issue":"12","key":"4002_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","volume":"69","author":"AO Clive","year":"2014","unstructured":"Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098\u2013104. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205285.","journal-title":"Thorax"},{"issue":"1","key":"4002_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13063-015-0563-y","volume":"16","author":"R Bhatnagar","year":"2015","unstructured":"Bhatnagar R, Kahan BC, Morley AJ, Keenan EK, Miller RF, Rahman NM. The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): Study protocol for a randomised controlled trial. Trials. 2015;16(1):48.","journal-title":"Trials"},{"issue":"9","key":"4002_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2213-2600(18)30288-1","volume":"6","author":"S Muruganandan","year":"2018","unstructured":"Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6(9):671\u201380. https:\/\/doi.org\/10.1016\/S2213-2600(18)30288-1.","journal-title":"Lancet Respir Med"},{"issue":"14","key":"4002_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/nejmoa1716883","volume":"378","author":"R Bhatnagar","year":"2018","unstructured":"Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med. 2018;378(14):1313\u201322. https:\/\/doi.org\/10.1056\/nejmoa1716883.","journal-title":"N Engl J Med"},{"issue":"11","key":"4002_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ciresp.2022.05.005","volume":"100","author":"JL Recuero D\u00edaz","year":"2022","unstructured":"Recuero D\u00edaz JL, Figueroa Alm\u00e1nzar S, G\u00e1lvez Mu\u00f1oz C, et al. Recommendations of the Spanish Society of Thoracic Surgery for the management of malignant pleural effusion. Cir Esp. 2022;100(11):673\u201383. https:\/\/doi.org\/10.1016\/j.ciresp.2022.05.005.","journal-title":"Cir Esp"},{"issue":"2","key":"4002_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/LBR.0000000000000632","volume":"27","author":"JM Porcel","year":"2020","unstructured":"Porcel JM, Torres M, Pardina M, Civit C, Salud A, Bielsa S. Predictors of indwelling pleural catheter removal and infection: a single-center experience with 336 procedures. J Bronchol Interv Pulmonol. 2020;27(2):86\u201394. https:\/\/doi.org\/10.1097\/LBR.0000000000000632.","journal-title":"J Bronchol Interv Pulmonol"},{"issue":"8","key":"4002_CR19","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1089\/jpm.2020.0695","volume":"24","author":"M Botana-Rial","year":"2021","unstructured":"Botana-Rial M, Ramos-Hern\u00e1ndez C, Lojo-Rodr\u00edguez I, et al. Cost effectiveness of malignant pleural effusion with indwelling catheter: systematic review. J Palliat Med. 2021;24(8):1206\u201312. https:\/\/doi.org\/10.1089\/jpm.2020.0695.","journal-title":"J Palliat Med"},{"key":"4002_CR20","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2012.121","author":"G Balestroni","year":"2015","unstructured":"Balestroni G, Bertolotti G. EuroQol-5D (EQ-5D): an instrument for measuring quality of life. Monaldi Arch Chest Dis. 2015. https:\/\/doi.org\/10.4081\/monaldi.2012.121.","journal-title":"Monaldi Arch Chest Dis"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04002-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04002-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04002-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:47:31Z","timestamp":1773060451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04002-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4002"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04002-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of\u00a0Tehran University of Medical Sciences\u00a0(Ethical Code:\u00a0IR.TUMS.IKHC.REC.1403.452). Written informed consent was obtained from all participants prior to enrollment. All methods were performed in accordance with the\u00a0Declaration of Helsinki\u00a0and relevant national\/institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (no individual personal data\/images are included).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"394"}}